DeepMed Research

Jiangsu Hengrui Medicine Co., Ltd

🇨🇳China

Country: 🇨🇳China

Ownership: -

Established: 1970-01-01

Employees: -

Market Cap: $38.9B

Website: http://www.hrs.com.cn/english/

Clinical Trials

A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma

Phase 2

Withdrawn

Conditions: Intrahepatic Cholangiocarcinoma

Interventions: Drug: Famitinib

First Posted Date: 2020-07-21

Last Posted Date: 2021-06-22

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Registration Number: NCT04479904

The Single, Multiple Dose and Food Effect Study of SHR2285 Tablets on Pharmacokinetics and Pharmacodynamics in Healthy Subjects

Phase 1

Completed

Conditions: Thrombosis

Interventions: Drug: SHR2285 tablet
Drug: Placebo

First Posted Date: 2020-07-15

Last Posted Date: 2021-09-28

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 104

Registration Number: NCT04472819

Locations: 🇨🇳
The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
🇨🇳
Peking University First Hospital, Beijing, Beijing, China

Multi-dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DDO-3055 Tablets in Patients With Anemia of Non-dialysis Chronic Kidney Diseases.

Phase 1

Conditions: Anemia Associated Chronic Kidney Disease

Interventions: Drug: DDO-3055 tablets
Drug: Placebo

First Posted Date: 2020-07-14

Last Posted Date: 2021-10-26

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 30

Registration Number: NCT04470063

Locations: 🇨🇳
Second Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
🇨🇳
Beijing Friendship Hospital,Capital Medical University, Beijing, Beijing, China
🇨🇳
Shenzhen Second People's Hospital, Shenzhen, Guangdong, China

and more 9 locations

Safety, Tolerability, Pharmacokinetics(PK), Pharmacodynamics(PD) and Food Effect of HRS9950 in Healthy and CHB Subjects

Phase 1

Completed

Conditions: Chronic Hepatitis b

Interventions: Drug: HRS9950
Drug: Placebo

First Posted Date: 2020-07-09

Last Posted Date: 2024-11-05

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 146

Registration Number: NCT04464733

Locations: 🇨🇳
Beijing Youan Hospital,Capital Medical University, Beijing, Beijing, China

A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects

Phase 1

Completed

Conditions: Advanced Solid Tumor

Interventions: Drug: Apatinib Mesylate
Drug: Repaglinide
Drug: Bupropion

First Posted Date: 2020-07-07

Last Posted Date: 2022-10-26

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 18

Registration Number: NCT04457180

Locations: 🇨🇳
The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China

A Study to Determine the Safety, Tolerability, and Efficacy of SHR-1209 in Patients With Familial Hypercholesterolemia

Phase 2

Conditions: Familial Hypercholesterolemia

Interventions: Drug: SHR-1209

First Posted Date: 2020-07-02

Last Posted Date: 2020-07-02

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 8

Registration Number: NCT04455581

A Phase I Study of SHR1459 in Healthy Subjects

Phase 1

Completed

Conditions: Health, Subjective

Interventions: Drug: SHR1459/Itraconazole

First Posted Date: 2020-07-02

Last Posted Date: 2021-10-18

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 20

Registration Number: NCT04455100

Locations: 🇨🇳
Shanghai General Hospital, Shanghai, Shanghai, China

Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy

Phase 3

Active, not recruiting

Conditions: HER2 Exon 20 Mutation
Non-squamous NSCLC

Interventions: Drug: Pyrotinib
Drug: Docetaxel

First Posted Date: 2020-06-25

Last Posted Date: 2023-03-08

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 151

Registration Number: NCT04447118

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States
🇧🇪
Antwerp University Hospital (UZA), Edegem, Belgium

and more 99 locations

A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: SHR-A1811

First Posted Date: 2020-06-24

Last Posted Date: 2023-07-21

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 226

Registration Number: NCT04446260

Locations: 🇺🇸
Gabrail Cancer Center, Canton, Ohio, United States
🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇦🇺
Macquarie University Hospital, Macquarie, New South Wales, Australia

and more 32 locations

A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Phase 1

Completed

Conditions: AML
MDS

Interventions: Drug: SHR-1702

First Posted Date: 2020-06-23

Last Posted Date: 2023-08-24

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 31

Registration Number: NCT04443751

Locations: 🇨🇳
Blood disease hospital of Chinese Academy of Medical Sciences, Tianjin, Tianjin, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy